A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors

Summary

This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with anticancer therapies in participants with selected advanced or metastatic solid tumors. This study will consist of 2 parts. In Part 1, INCB123667 will be administered as monotherapy and in Part 2, INCB123667 will be administered in combination with anticancer therapies of interest. Each part will comprise a dose escalation portion (Parts 1a and 2a, respectively) and a dose-expansion portion (Parts 1b and 2b, respectively).

Eligibility

Age range

18+ years

Sex

All

Healthy volunteers

No

Interventions

• Drug
  INCB0123667

  25 mg tablets

• Drug
  Palbociclib

  Palbociclib will be administered at protocol defined dose.

• Drug
  Bevacizumab

  Bevacizumab will be administered at protocol defined dose.

• Drug
  Olaparib

  Olaparib will be administered at protocol defined dose.

• Drug
  Paclitaxel

  Paclitaxel will be administered at protocol defined dose.

• Drug
  Ribociclib

  Ribociclib will be administered at protocol defined dose.

• Drug
  Fulvestrant

Locations (42)